Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Disclosing Drug Development Failures Would Aid Regulatory Science, FDA’s Hamburg Says

Executive Summary

FDA is making the case for increased data-sharing and disclosure about drug development failures in the name of bolstering regulatory science.

You may also be interested in...



Orphan Disclosures Could Increase Under Tweaks Proposed By FDA

Agency considering whether to tell public if sponsors have submitted annual product development reports as part of proposed rule clarifying portions of 1992 Orphan Drug Regulations.

Regulatory Reform: FDA Pushes Back, Asks For Specific Problems To Fix

FDA pushed back against a growing number of calls for regulatory reform during the U.S. Conference on Rare Diseases and Orphan Products, mainly because they were just generalized complaints.

Regulatory Reform: FDA Pushes Back, Asks For Specific Problems To Fix

FDA pushed back against a growing number of calls for regulatory reform during the U.S. Conference on Rare Diseases and Orphan Products, mainly because they were just generalized complaints.

Related Content

Topics

UsernamePublicRestriction

Register

PS053283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel